TBC
TBC
Validation Strategies for Pharmaceutical Patents in Europe
Special Report
The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries. The choice typically factors in costs, business interests, likely markets and market size, possible manufacturing and import locations and the regulatory framework in Europe.
This report explores these choices and factors using publicly available data, seeking to answer questions such as:
- Which countries are most commonly picked by patent holders at the EPO?
- Is the distribution the same for pharmaceutical patents?
- Where does “big pharma” choose to validate?
- What factors might affect the choice of countries?
Read our blogs
.png)
BioTryp’s radical new treatment for bacterial infection
Cambridge University spin-out BioTryp is developing inhibitors that disrupt a signalling mechanism of bacteria to prevent the formation of biofilms, thereby reducing infection. Forward: features are ...
We are a leading force in EPO oppositions
When it comes to opposing or defending European patents, experience matters. A look at our track record across both offensive and defensive oppositions over the last 12 years highlights not only the ...
-1.png)
UPC Weekly - Three darts all miss – PI based on three patents refused due to validity concerns and insufficient proof of infringement
2026 Week 5 For good or bad, it is now clear that inter partes preliminary injunction (PI) proceedings at the UPC end up being mini-trials of the substantive issues. In Guardant Health v. Sophia ...
Round up of recent EPO Board of Appeal decisions relating to antibodies
We have carried out our annual review of EPO Board of Appeal decisions published up to the end of 2025 where the claimed subject matter relates to antibodies. We have selected those decisions that ...
Most opposed patents of 2025
Writing this year’s overview prompted déjà vu and a quick check of 2024’s most opposed patents confirmed that the same innovators feature at the top of the list: patents in the name of Novartis (for ...
UPC Weekly - Limits on jurisdiction outside the UPC when invalidity looms
2026 Week 4 The extent of the jurisdiction asserted by the UPC is a hot topic at the moment. On 22 January 2026, the UPC Court of Appeal (CoA) held the oral hearing in the appeal against the ...
Mewburn Ellis
FORWARD MAGAZINE
Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.